Setting a standard for personal digital sperm analysis

Projektinformationen

QS Mobile

ID Finanzhilfevereinbarung: 789952

DOI

10.3030/789952

Projekt abgeschlossen

EK-Unterschriftsdatum 25 November 2017

Startdatum 1 Oktober 2017

Enddatum 28 Februar 2018

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

BIOPHOS SA
Switzerland

Periodic Reporting for period 1 - QS Mobile (Setting a standard for personal digital sperm analysis)

Berichtszeitraum: 2017-10-01 bis 2018-02-28

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Report summary

In this market feasibility study that was carried out in November – February 2018 we have assessed the commercial & market feasibility for QS.Mobile as well as the economic & financial feasibility of the project.
We have arrived at the following major results:
• Based on demographics and socioeconomic data we have identified key target groups for our solution for a global market
• Identified the demand for a Male Fertility Diagnostic solution and estimated the market value.
• We reviewed the go-to-market strategy and made necessary adjustment, verified our 5 key markets.
• Identified a multiple sales and distribution proposition including cost breakdown.
• Established scientific and commercial partners in few selected markets.
• Defined the impact of the regulatory landscape and new GDRP directives to be implemented in the development
• Concluded the reimbursement strategy.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Work performed

In this feasibility study we have:
• Selected 5 strategic markets verified the business model and strategy.
• Assessed key features for the GDPR directives to be implemented during the development
• Assessed the recycling strategy
• Prepared the final market-research strategy.
• Identified and selected possible manufacturing partners and defined the development cost.
• Reviewed a pricing model.
• Identified cost for major parts of the production
• Initiated a study with scientific partner to be published in 2018

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Final results
In this feasibility study we have revalidated and confirmed the market potential and the business opportunity for QS.Mobile. In addition we have identified a clear sales and marketing strategy.
We have started the first phase of commercialization with B2B customers since January 2018 and expect to have 4 selected markets covered with at least one partner in each market during 2018. In parallel with the market entry for B2B the objective is to finalize the QS.Mobile development.
For this purpose, we will pursue an application for the SME Instrument Phase 2 grant in May 2018 to industrialize the technology, solve the current technical issues and drive the production costs down from current price per prototype.
The shareholders and founders are committed to invest into QS.Mobile should we succeed with our SME Instrument Phase 2 application.

biophos-logo.jpg